The α-gal Syndrome - Investigating Immune Reactions to Tick Bites

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

100 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-07-01

Study Completion Date

2027-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Tick bites can transmit pathogens, but they can also induce a food allergy to mammalian meat. The goal of this clinical trial is to follow immune response and antibody build-up in individuals bitten by a tick. Participants are invited to enroll within 48 hours after the tick removal and donate some blood. The tick is also collected and analysed. Researchers will then try to answer the following questions:

* Was the tick infected with parasites?
* Did the participant make antibodies against tick proteins or tick-borne parasites?
* Did the participant develop IgE antibodies against the alpha-Gal sugar? The alpha-Gal sugar is present on mammalian meat, and ticks can transmit the alpha-Gal sugar to the host during their blood meal. Humans recognize the alpha-Gal sugar as foreign and some individuals will build IgE antibodies in response. These IgE antibodies against alpha-Gal can lead to a food allergy to red meat, also known as alpha-Gal syndrome.

Researchers will compare a group of participants that develop IgE against the alpha-Gal sugar with participants that will not. They want to find out if there are specific immune features that differentiate the 2 groups.

Participants will:

* Enroll after a recent tick bite within 48 hours after tick removal: they will be asked to donate some blood and fill out a questionnaire.
* Visit the clinic 4 to 6 weeks later for a follow-up sample and questionnaire.
* Visit the clinic 3 months after the tick bite for allergy tests if they have been selected for this 3rd visit.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Analysis of the Role of IgE Proteoforms in Health and Disease

NCT07328178

Anaphylaxis Mastocytosis X-linked Agammaglobulinaemia +6 more

RECRUITING

Gluten-free Diet in Gluten-genetically Predisposed Subjects

NCT00677495

Genetic Predisposition to Disease Celiac Disease

COMPLETED NA

Study in Allergic Adults to Support the Development of Immunological Assays

NCT01320137

Immunologic Tests

COMPLETED NA

Physical Fitness in Celiac Disease Patients - the Effect of a Gluten Free Diet

NCT04012736

Celiac Disease in Children

TERMINATED

Biomarkers in Food Allergy Diagnosis

NCT04604912

Allergy;Food

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Ticks bearing pathogens can transmit infectious diseases such as Lyme borreliosis, tick-borne encephalitis and others. Recently, a non-infectious human disease, namely the alpha-gal syndrome (AGS), was shown to be of tick origin. AGS, characterized by the presence of IgE antibodies directed against the carbohydrate galactose-α-1,3-galactose (alpha-gal or α-gal) is also known as 'red meat allergy'. Unlike the more 'classical' food allergies, symptoms are delayed and may appear several hours after ingestion of mammalian meat or dairy products, often hampering a timely clinical diagnosis.

Individuals with occupational or recreational outdoor activities often experience frequent tick bites and they have a higher risk of developing AGS. There are still many questions regarding the etiology and the development of the disease. Not every tick bite will lead to sensitization and it is presently unclear how the human immune system reacts to tick bites and why the initial events after a tick bite will either lead to a short-lived natural immune defense or shift the immune response to an uncontrolled Th2 response which potentially leads to allergic disease. Tick bites also bear the risk of pathogen transmission, and there is a clear need for monitoring tick bites for public health purposes.

The present study will investigate early peripheral immune responses in individuals bitten by a tick. The investigators hypothesize that the pathway to allergic sensitization to α-gal is already predictable from the peripheral immune response early after a tick bite and that an adequate protective defense against ticks can be distinguished from an allergic inflammatory response by discrete marker signatures shortly after the tick bite. Additionally, the investigators will collect population-based tick surveillance data which will be an important contribution to public health. The advertising of the study for recruitment purposes will be combined with information on tick avoidance and monitoring in case of a bite, thus contributing to public awareness and education.

The objectives of the study are:

i) To determine peripheral inflammatory protein and cellular as well as intracellular signatures leading to either a normal and self-limited human immune defense or to allergic sensitization; ii) To generate surveillance data on tick-related diseases (pathogens/allergy) in individuals experiencing a tick bite.

In order to achieve these objectives, the researchers will perform a deep immune analysis of blood samples collected upon a tick bite by using multi-omics and high-resolution techniques. They will longitudinally follow 100 study participants for several weeks and determine their serological status. Blood will be collected at day 1, then 4 to 6 weeks after the bite. For 2 subgroups of participants, selected for their sensitization to a-Gal and a control group without a-Gal sensitization, a 3rd visit is planned 8 to 12 weeks after the bite for clinical assessment. A questionnaire on the 2 first visits will collect data regarding tick bite history, current tick bite, current health status, allergic disease, diet for meat and dairy products.

The tick responsible for the bite will also be collected. The species will be identified and analysed for tick-borne pathogens by PCR. The identification of the tick species and search for tick-borne pathogens will generate crucial data that are important for tick and tick-related disease surveillance in Luxembourg.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Alpha-Gal Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

a-Gal sensitized participants

Following the second visit 4 to 6 weeks after the tick bite, participants with specific alpha-Gal IgE levels above 0.1 kU/L are assigned to this group of a-Gal sensitized participants.

No interventions assigned to this group

a-Gal non-sensitized participants

Following the second visit 4 to 6 weeks after the tick bite, participants with specific alpha-Gal IgE levels below 0.1 kU/L are assigned to this group of a-Gal non-sensitized participants.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Individuals aged ≥ 18 years, Male and Female.
* Experience of a tick bite: the tick has been removed less than 48 hours ago, or the tick is still attached to the skin and can be removed on site by the study nurse.
* Tick available for analysis.
* Informed consent signed.

Exclusion Criteria

* Individuals \< 18 years of age, Male or Female.
* Individuals with an acute viral/bacterial inflammation.
* Individuals with an immune deficiency or under immunosuppressive treatments.
* Individuals in receipt with immunotherapy with omalizumab.
* Individuals with neurological diseases / impaired cognitive disorder.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes